Inhibrx Biosciences Expands Credit Facility to $500 Million to Boost Liquidity

Key Facts

In a move aimed at strengthening its financial position and supporting clinical research, Inhibrx Biosciences has announced a significant expansion of its credit facilities. According to reports, the company entered into an amended loan agreement with Oxford Finance to increase the total facility to $500 million. This expansion includes a new tranche of up to $325 million, with $100 million funded immediately to advance the development of its biologic therapeutic candidates.

This credit expansion comes as biotechnology firms seek to secure longer cash runways amid market volatility. Compared to sector peers, securing half a billion dollars in financing reflects lender confidence in Inhibrx's pipeline, particularly as the company focuses on oncology and rare disease treatments. Per market data, this type of debt financing serves as a strategic alternative to equity issuance, which could dilute shareholder value under current market conditions.

Operationally, this additional liquidity will assist in accelerating the company's clinical trial timelines. On the macroeconomic front, traders are looking ahead to the U.S. Monetary Policy Report on July 10, 2026, which may influence future borrowing costs for firms utilizing flexible credit facilities.